As the healthcare sector continues to thrive amid global health challenges and an ageing population, savvy investors are increasingly eyeing opportunities in this resilient market. September presents a particularly compelling window to invest in some standout healthcare stocks that are not only performing well but also have strong potential for future growth. Among these, OncoSil Medical, Imugene Limited, and Telix Pharmaceuticals are three stocks that should be on your radar for immediate consideration.
OncoSil Medical
OncoSil Medical (ASX: OSL) is rapidly becoming a name synonymous with innovation in cancer treatment. The company’s groundbreaking product, the OncoSil™ device, is a breakthrough therapy designed to treat pancreatic cancer by delivering targeted radiation directly to the tumour. This approach has shown significant promise, especially in cases where surgical options are limited, providing hope to patients who previously had few alternatives.
In recent months, OncoSil Medical’s stock has seen a steady upward trend, arguably driven by the strategic investments and leadership involvement of industry veteran investor Peter Hall. Their influence has significantly impacted the company’s trajectory, positioning OncoSil Medical for greater success.
In Q4 FY24, the number of doses used in commercial treatments increased by a remarkable 78% compared to Q4 FY23 and was 2.7 times the average volume for the first three quarters of FY24. This growth highlights the effectiveness of OncoSil Medical’s strategic initiatives aimed at making their innovative cancer treatment solutions more accessible to healthcare providers and patients alike.
The ongoing success of the OncoSil device is not only improving patient outcomes but also driving investor confidence and is set to be a leader in the oncology space. Given its recent achievements and the strong demand for its products, OncoSil Medical is a healthcare stock you’ll want to buy hand over fist in September.
Imugene Limited
Imugene Limited (ASX: IMU) is another Australian biotech company making waves in the healthcare sector, particularly in the field of immuno-oncology. The company focuses on developing innovative cancer immunotherapies that harness the body’s immune system to target and destroy cancer cells. Imugene’s pipeline includes a range of novel therapies designed to treat various cancers, positioning it as a key player in the fight against this devastating disease.
Imugene’s lead product, HER-Vaxx, is a B-cell immunotherapy aimed at treating HER-2 positive gastric cancer. The therapy has shown promising results in clinical trials, sparking increased interest from both the medical community and investors alike. In addition to HER-Vaxx, Imugene is also developing several other candidates, including CF33, an oncolytic virus that selectively infects and kills cancer cells while sparing healthy tissue.
With a robust pipeline of therapies and ongoing clinical trials, Imugene offers significant upside potential for investors looking to tap into the future of cancer treatment. As the company continues to advance its pipeline and achieve key milestones, Imugene is a healthcare stock that could deliver substantial returns, making it a must-buy in September.
Telix Pharmaceuticals
Telix Pharmaceuticals (ASX: TLX) is a biotechnology company specialising in the development of diagnostic and therapeutic radiopharmaceuticals, particularly for oncology. The company’s innovative approach combines medical imaging with targeted radiation therapy, allowing for more precise and effective treatment of cancer.
Telix’s lead product, Illuccix, is a PET imaging agent used for prostate cancer. The company has already received approval for Illuccix in several major markets, including the United States and Europe, and is actively expanding its global footprint. This has led to significant revenue growth and has positioned Telix as a leader in the field of radiopharmaceuticals.
Beyond Illuccix, Telix is developing a range of other products targeting various cancers, including kidney cancer and brain metastases. With a robust pipeline of products in different stages of clinical development, Telix offers investors multiple avenues for growth.
Telix’s innovative technology and expanding market presence have not gone unnoticed by investors. The company’s stock has been on an upward trajectory, reflecting the strong demand for its products and the potential for future growth. As Telix continues to roll out its products globally and advance its pipeline, it is well-positioned to capitalise on the growing need for advanced cancer diagnostics and treatments. For investors looking to gain exposure to cutting-edge healthcare technology, Telix Pharmaceuticals is a stock worth buying hand over fist in September.
The healthcare sector remains one of the most resilient and promising areas for investment, particularly as the demand for advanced medical treatments continues to rise. OncoSil Medical, Imugene Limited, and Telix Pharmaceuticals are three ASX-listed companies that stand out for their innovative approaches and strong growth potential. As they continue to achieve key milestones and expand their market presence, these stocks offer significant upside for investors looking to capitalise on long-term trends in healthcare. If you’re considering where to allocate your funds in September, these healthcare stocks should be at the top of your list.
